中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
25期
19-22
,共4页
张宁%刘学文%刘轶丹%张信芳
張寧%劉學文%劉軼丹%張信芳
장저%류학문%류질단%장신방
癫痫%韦氏记忆量表%蒙特利尔认知评估量表%事件相关电位%小牛血清去蛋白肠溶胶囊
癲癇%韋氏記憶量錶%矇特利爾認知評估量錶%事件相關電位%小牛血清去蛋白腸溶膠囊
전간%위씨기억량표%몽특리이인지평고량표%사건상관전위%소우혈청거단백장용효낭
Epilepsy%Wechlors memory scale%Montreal cognitive assessment%Event related potentials%Deproteinised calf serum enteric-coated capsules
目的 检测癫痫患者的认知功能,探讨小牛血清去蛋白肠溶胶囊(DCSECC)对脑功能的影响及作用机制.方法 将66例癫痫患者按抽签法随机分为试验组和对照组,每组33例,两组均规范服用抗癫痫药,试验组口服DCSECC 5 mg/d,连续服用3个月.分别于治疗前及治疗后1,2,3个月行韦氏记忆量表(WMS,转换为记忆商)和蒙特利尔认知评估量表(MoCA)评分,检测事件相关电位P300潜伏期和丙二醛浓度.并与33例健康体检者(健康组)进行比较.结果 试验组和对照组治疗前记忆商、MoCA评分均明显低于健康组[(80.4±14.2),(79.6±13.9)分比(103.2±30.1)分,(13.5±4.5),(12.9±3.9)分比(28.8±8.7)分],P300潜伏期、丙二醛明显大于健康组[(380.8±49.7),(389.5±50.4) ms比(309.8±44.7) ms,(5.0±1.8),(4.8±1.7) μmol/L比(2.2±0.6)μmol/L],差异有统计学意义(P＜0.05);试验组治疗后3个月记忆商[(96.5±18.3)分]、MoCA评分[(26.8±7.7)分]较治疗前明显增加,P300潜伏期[(321.3±36.1) ms]及治疗后2,3个月丙二醛[(3.02±1.04),(2.99±1.01)μmol/L]较本组治疗前明显降低,差异有统计学意义(P＜0.05);对照组治疗前后记忆商、MoCA评分比较差异无统计学意义(P＞0.05).治疗过程中未出现与服用DCSECC有关的明显不良反应.结论 癫痫患者认知功能明显减退,DCSECC能显著改善患者的认知功能,其作用机制可能是通过抗氧化实现的.
目的 檢測癲癇患者的認知功能,探討小牛血清去蛋白腸溶膠囊(DCSECC)對腦功能的影響及作用機製.方法 將66例癲癇患者按抽籤法隨機分為試驗組和對照組,每組33例,兩組均規範服用抗癲癇藥,試驗組口服DCSECC 5 mg/d,連續服用3箇月.分彆于治療前及治療後1,2,3箇月行韋氏記憶量錶(WMS,轉換為記憶商)和矇特利爾認知評估量錶(MoCA)評分,檢測事件相關電位P300潛伏期和丙二醛濃度.併與33例健康體檢者(健康組)進行比較.結果 試驗組和對照組治療前記憶商、MoCA評分均明顯低于健康組[(80.4±14.2),(79.6±13.9)分比(103.2±30.1)分,(13.5±4.5),(12.9±3.9)分比(28.8±8.7)分],P300潛伏期、丙二醛明顯大于健康組[(380.8±49.7),(389.5±50.4) ms比(309.8±44.7) ms,(5.0±1.8),(4.8±1.7) μmol/L比(2.2±0.6)μmol/L],差異有統計學意義(P＜0.05);試驗組治療後3箇月記憶商[(96.5±18.3)分]、MoCA評分[(26.8±7.7)分]較治療前明顯增加,P300潛伏期[(321.3±36.1) ms]及治療後2,3箇月丙二醛[(3.02±1.04),(2.99±1.01)μmol/L]較本組治療前明顯降低,差異有統計學意義(P＜0.05);對照組治療前後記憶商、MoCA評分比較差異無統計學意義(P＞0.05).治療過程中未齣現與服用DCSECC有關的明顯不良反應.結論 癲癇患者認知功能明顯減退,DCSECC能顯著改善患者的認知功能,其作用機製可能是通過抗氧化實現的.
목적 검측전간환자적인지공능,탐토소우혈청거단백장용효낭(DCSECC)대뇌공능적영향급작용궤제.방법 장66례전간환자안추첨법수궤분위시험조화대조조,매조33례,량조균규범복용항전간약,시험조구복DCSECC 5 mg/d,련속복용3개월.분별우치료전급치료후1,2,3개월행위씨기억량표(WMS,전환위기억상)화몽특리이인지평고량표(MoCA)평분,검측사건상관전위P300잠복기화병이철농도.병여33례건강체검자(건강조)진행비교.결과 시험조화대조조치료전기억상、MoCA평분균명현저우건강조[(80.4±14.2),(79.6±13.9)분비(103.2±30.1)분,(13.5±4.5),(12.9±3.9)분비(28.8±8.7)분],P300잠복기、병이철명현대우건강조[(380.8±49.7),(389.5±50.4) ms비(309.8±44.7) ms,(5.0±1.8),(4.8±1.7) μmol/L비(2.2±0.6)μmol/L],차이유통계학의의(P＜0.05);시험조치료후3개월기억상[(96.5±18.3)분]、MoCA평분[(26.8±7.7)분]교치료전명현증가,P300잠복기[(321.3±36.1) ms]급치료후2,3개월병이철[(3.02±1.04),(2.99±1.01)μmol/L]교본조치료전명현강저,차이유통계학의의(P＜0.05);대조조치료전후기억상、MoCA평분비교차이무통계학의의(P＞0.05).치료과정중미출현여복용DCSECC유관적명현불량반응.결론 전간환자인지공능명현감퇴,DCSECC능현저개선환자적인지공능,기작용궤제가능시통과항양화실현적.
Objective To investigate the effect of deproteinised calf serum enteric-coated capsules (DCSECC) on cognitive function of patients with epilepsy.Methods Sixty-six patients were randomly divided into two groups including experimental group who received DCSECC 5 mg/d,3 times a day and antiepileptics,and control group who received antiepileptics.To detect the cognitive function by means of Wechlors memory scale (WMS),Montreal cognitive assessment (MoCA),event related potentials (P300) latency period and malondialdehyde (MDA) before treatment and after treatment for 1,2,3 months,and compared with 33 healthy subjects controls (healthy group).Results Compared with healthy group,the scores of memory quotient (MQ) and MoCA were signifiantly decreased in experimental group and control group [(80.4 ± 14.2),(79.6 ± 13.9) scores vs.(103.2 ± 30.1) scores; (13.5 ± 4.5),(12.9 ± 3.9) scores vs.(28.8 ±8.7) scores],in the mean time,P300 latency period and MDA were signifiantly prolonged [(380.8 ± 49.7),(389.5 ± 50.4) ms vs.(309.8 ± 44.7) ms ; (5.0 ± 1.8),(4.8 ± 1.7) μ mol/L vs.(2.2 ± 0.6) μ mol/L],there was significant difference (P ＜ 0.05).Compared with the control group after treatment for 3 months,the scores of MQ and MoCA in experimental group [(96.5 ± 18.3) scores,(26.8 ± 7.7) scores] were increased and P300 latency period [(321.3 ±36.1) ms] was shortened,there were significant differences (P ＜ 0.05).The level of MDA decreased significantly in experimental group after 2,3 months treatment[(3.02 ± 1.04),(2.99 ± 1.01) μ mol/L],there was significant difference(P＜ 0.05).The scores of MQ and MoCA in control group after treatment had no significant difference compared with before treatment (P ＜ 0.05).Conclusions The cognitive function in patients with epilepsy is decreased.DCSECC medical treatment can improve the cognitive function by means of antioxidant activity.
